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FROM THE ARCHIVE
 
What tumors need: a brief history of angiogenesis
 
The field of angiogenesis began in the early 1970s when Judah Folkman 
proposed that tumor growth would be halted if the tumor were deprived of 
a blood supply. Thirty years later, Folkman’s controversial idea is now widely 
accepted and angiogenesis inhibitors hold great promise for the treatment 
of cancer.
 
Dog thyroids and guinea pig eyes
 
Judah Folkman’s radical idea began with
a mundane task. In 1961, Folkman, then
a third year surgical resident, was drafted
by the navy and charged with optimiz-
ing the use of freeze-dried hemoglobin
as an alternative to fresh blood. The he-
moglobin preparations were tested for
the ability to sustain the viability of dog
thyroid glands and, later, the growth of
mouse tumor cells implanted in the
glands. The implanted tumors stopped
growing after reaching a modest size,
but grew explosively if transplanted back
into a mouse. Intrigued, Folkman ex-
amined the tumors under the micro-
scope and found a network of tiny
blood vessels inside the retransplanted
tumor cells. He saw no vessels in the
original thyroid tumors (1).
The data were consistent with work
from Harry Greene, who had shown
long before that growth of rabbit tumors
transplanted into the anterior chamber
of the guinea pig eye coincided with the
growth of new blood vessels (angiogen-
esis). Tumors that remained viable but
did not grow had no visible blood supply
(2). Folkman thus proposed that angio-
genesis and tumor growth might go hand
in hand. He even stuck his neck out and
speculated that “anti-angiogenesis” strat-
egies might eventually be used to treat
cancer (3). These ideas were widely crit-
icized, as the prevailing opinion at that
time was that tumor growth did not
depend on angiogenesis.
 
Making the connection
 
Folkman and his student Michael Gim-
brone took advantage of the eye trans-
plant model to demonstrate that tumor
fragments refused to grow if placed too
far away from blood vessels. By contrast,
tumor fragments implanted directly onto
the iris—which has abundant blood
vessels nearby—grew to 16,000 times
their original size in only 2 weeks (4).
Moving the distant, dormant tumors
closer to the iris jump-started their
growth. This suggested that tumor dor-
mancy was caused not by cell cycle
arrest or immune control, as most tumor
biologists believed, but by a lack of
blood supply.
But how did proximity to blood
vessels  dictate tumor growth? Previous
studies had shown that tumor-stimulated
vessel growth did not require direct
contact between tumor and host tissue
(5, 6), indicating that a soluble factor was
at work. This made sense to Folkman,
who reasoned that a soluble factor
would be more likely to reach nearby
than distant blood vessels. He and his
colleagues later isolated a soluble tumor-
derived factor that triggered endothelial
cell proliferation and growth of capillaries
in rat skin (7). They named the factor
tumor angiogenesis factor (TAF). Both
this and the eye transplant study were
published in the
 
 Journal of Experimental
Medicine
 
.
 
Angiogenesis research explodes
 
With time and increasing evidence, the
field was convinced of Folkman’s an-
giogenesis theory. “By the mid-1980s,”
Folkman says, “we began to convert
our critics into competitors.” And al-
though the identity of TAF in his orig-
inal preparation was never revealed,
Folkman’s group and many others
went on to discover numerous tumor-
derived angiogenesis factors including
basic fibroblast growth factor, angio-
genin, and vascular endothelial growth
factor (VEGF) (for review see reference
8). Later genetic studies in mice con-
firmed the importance of these factors
for tumor growth.
The description of natural and syn-
thetic angiogenesis inhibitors followed,
several of which are now in clinical
trials  and one of which (Avastin) is
FDA approved for the treatment of co-
lon cancer. Folkman’s hope for the fu-
ture is that anti-angiogenesis therapy
could be initiated based on diagnostic
biomarkers, even before the tumor
reveals its location in the body, thus
stopping  cancer before it really ever
gets started.
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